The Apothecary Pharma recall of compounded tirzepatide and recent FDA moves have patients asking whether their copycat shots are safe.
Recap by typeshit. Full story at USA TODAY on MSN.
Dr. Woo points to the official position of the AAO and NANOS on whether routine eye exams just to check for NAION are needed.
USA TODAY covers the copycat GLP-1 crackdown, from the Apothecary Pharma recall to an import alert on a Chengdu factory. Novo says it has filed over 130 lawsuits.
A fitness coach says clients on GLP-1 drugs often focus on how fast weight drops instead of whether they eat enough protein.
She points to women getting pregnant unexpectedly after GLP-1s restore ovulation, and questions the mixed messages women get about these drugs and fertility.
Doctors quoted by Men's Journal raise concerns about how much GLP-1 users are paying for add-on supplements each month.
It cites a Gallup survey finding 11% of Americans now take a GLP-1, up from 3% in 2024, and explains where compounded versions fit under tighter FDA rules.
Loading…